Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 1, 1997, Pages 50-59

  Lefèvre, Gilbert ^a   Duval, Martine ^b   Gauron, Sonia ^b   Brookman, Laurence J ^b   Rolan, Paul E ^b   Morris, Thomas M ^b   Piraino, Anthony J ^b   Morgan, John M ^b   Palmisano, Maria ^b   Close, Philippe ^b  

^a NOVARTIS PHARMA K K   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DESULFATOHIRUDIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; ERYTHEMA; HEADACHE; HEMATOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; THORAX PAIN;

ADULT; AGED; ANTICOAGULANTS; CREATININE; FEMALE; HIRUDINS; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX;

EID: 12644267274     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90151-X     Document Type: Article

References (29)

1. Markwardt F. Hirudin as an inhibitor of thrombin. Methods Enzymol 1970;19:924-32.
2. Hoet B, Close P, Vermylen J, Verstraete M. Hirudo medicinalis and hirudin. In: Poller L, editor. Recent advances in blood coagulation. New York: Churchill Livingstone, 1991:223-44.
3. Grossenbacher H, Auden JAL, Bill K, Liersch M, Märki W. Isolation and characterisation of recombinant desulfatohirudin from yeast, a highly selective thrombin inhibitor [abstract]. Thromb Res 1987;(7 suppl):34.
4. Meyhack B, Heim J, Rink H, Zimmermann W, Märki W. Desulfatohirudin, a specific thrombin inhibitor: expression and secretion in yeast [abstract]. Thromb Res 1987;(7 suppl):33.
5. Märki WE, Wallis RB. The anticoagulant and antithrombotic properties of hirudins. Thromb Haemost 1990;64:344-8.
6. Talbot M. Biology of recombinant hirudin (CGP 39 393): a new prospect in the treatment of thrombosis. Semin Thromb Hemost 1989;15:293-301.
7. Talbot M, Ambler J, Butler KD, Findley VS, Mitchel KA, Peter RF, et al. Recombinant desulfatohirudin (CGP 39 393) anticoagulant and antithrombotic properties in vivo. Thrombos Haemostas 1989;61:77-80.
8. Agnelli G, Pascucci C, Cosmi B, Nenci GC. The comparative effects of recombinant hirudin (CGP 39 393) and standard heparin on thrombus growth in rabbits. Thromb Haemost 1990;63:204-7.
9. Gray E, Watton J, Barrowcliffe TW, Thomas DP. Experimental studies on a recombinant hirudin CGP 39 393. Thromb Haemost 1991;63:355-9.
10. Marbet GA, Verstraete M, Kienast J, Graf P, Hoet B, Tsakiris DA, et al. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers. J Cardiovasc Pharmacol 1993;22:364-72.
11. Verstraete M, Nurmohamed M, Kienast J, Siebeck M, Silling-Engelhardt G, Duller H, et al. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. J Am Coll Cardiol 1993;22:1080-8.
12. Hoet B, Tornai I, Arnout J, Close P, Vermylen J, Verstraete M. Open study of intravenous recombinant hirudin (CGP 39393) on platelet function and coagulation in healthy volunteers. Drug Invest 1994;7:127-33.
13. Cardot JM, Lefèvre G, Godbillon J. Pharmacokinetics of rec-hirudin in healthy volunteers after i.v. administration. J Pharmacokinet Biopharm 1994;22:147-56.
14. Markwardt F, Hauptmann J, Nowak G, Walsmann P. Pharmacological studies on the antithrombotic action of hirudin in experimental animals. Thromb Haemost 1982;47:226-9.
15. Markwardt F, Nowak G, Stürzebecher J, Walsmann P. Studies on the pharmacokinetics of hirudin. Biomed Biochim Acta 1987;46:237-44.
16. Markwardt F, Fink G, Kaiser B, Klöcking HP, Nowak G, Richter M, et al. Pharmacological survey of recombinant hirudin. Pharmazie 1988;43:202-7.
17. Nowak G, Markwardt F, Fink E. Pharmacokinetics studies with recombinant hirudin in dogs. Folia Haematol (Leipz) 1988;115:70-4.
18. Markwardt F, Kaiser B, Nowak G. Studies on antithrombotic effects of recombinant hirudin. Thromb Res 1989;54:377-88.
19. Markwardt F. Development of hirudin as an antithrombotic agent. Semin Thromb Hemost 1989;15:269-82.
20. Bichler J, Fichtl B, Siebeck M, Fritz H. Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration. Arzneimittelforschung 1988;38:704-10.
21. Meyer BH, Luus HG, Müller FO, Badenhorst PN, Röthig HJ. The pharmacology of recombinant hirudin, a new anticoagulant. S Afr Med J 1990;78:268-70.
22. Stringer KA, Lindenfeld JA. Hirudins: antithrombin anticoagulants. Ann Pharmacother 1992;26:1535-40.
23. Waldmeier F, Graf P, Schär M. Renal excretion and metabolism of r-hirudin (CGP 39393) in volunteers following intravenous infusion. Presented at the Pharma-Protein and Peptide Symposium; 1993 April 15; Zürich. Poster 3/Abstract 5.
24. Spinner S, Scheffauer F, Maschler R, Stöffler G. A hirudin catching ELISA for quantitating the anticoagulant in biological fluids. Thromb Res 1988;51:617-25.
25. Schlaeppi JM, Vekemans S, Rink H, Chang JY. Preparation of monoclonal antibodies to hirudin and hirudin peptides: a method for studying the hirudin-thrombin interaction. Eur J Biochem 1990;188:463-70.
26. Bocci V. Catabolism of therapeutic proteins and peptides with implications for drug delivery, Adv Drug Deliv Rev 1990;4:149-69.
27. Maack T, Hyung Park C, Camargo MJF. Renal filtration, transport, and metabolism of proteins. In: Seldin DW, Giebisch G, editors. The kidney: physiology and pathophysiology. New York: Raven Press, 1992;3005-35.
28. Bichler J, Baynes JW, Thorpes SR. Catabolism of hirudin and thrombin-hirudin complexes in the rat. Biochem J 1993;296:771-6.
29. Nowak G, Bucha E, Gööck T, Thieler H, Markwardt F. Pharmacology of r-hirudin in renal impairment. Thromb Res 1992;66:707-15.